# Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer

> **NCT01296763** · PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 18 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Cisplatin
- **DRUG:** Olaparib (for levels 1 and 5)
- **DRUG:** Olaparib (for dose level 2)
- **DRUG:** Mitomycin-C

## Key facts

- **NCT ID:** NCT01296763
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2014-01
- **Final completion:** 2016-02
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2016-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01296763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01296763, "Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01296763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*